Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY23 results · Jan–Mar 2023
Glenmark Pharmaceuticals reported revenue from operations of ₹3,373.72 crore (up 11.7% from Q4 FY22) and net loss of ₹403.14 crore for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,373.72 | 3,019.15 | +11.7% | 3,463.86 | −2.6% |
| Other income | (40.21) | 107.20 | Turned loss | 76.42 | Turned loss |
| Total income | 3,333.50 | 3,126.35 | +6.6% | 3,540.27 | −5.8% |
| Profit before tax | (490.77) | 269.69 | Turned loss | 471.00 | Turned loss |
| Net profit for the period | (403.14) | 172.57 | Turned loss | 290.76 | Turned loss |
| EPS, basic (₹) | (15.18) | 5.51 | Turned loss | 9.66 | Turned loss |
| Net margin (%) | -11.9 | 5.7 | 8.4 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,939.05 | 1,785.54 | +8.6% | 2,161.47 | −10.3% |
| Other income | 232.97 | 178.98 | +30.2% | 89.73 | +159.6% |
| Total income | 2,172.01 | 1,964.53 | +10.6% | 2,251.20 | −3.5% |
| Profit before tax | (313.32) | 224.78 | Turned loss | 589.13 | Turned loss |
| Net profit for the period | (137.47) | 205.60 | Turned loss | 430.50 | Turned loss |
| EPS, basic (₹) | (4.87) | 7.29 | Turned loss | 15.26 | Turned loss |
| Net margin (%) | -7.1 | 11.5 | 19.9 |
Consolidated
- Filed with BSE
- 22 May 2023, 15:17 IST
- Board meeting
- 19 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 May 2023, 15:17 IST
- Board meeting
- 19 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE